Given the aforementioned findings in the literature, we predicted that PD patients relative to controls, with the DAT1 10/10 repeat genotype, compared with DAT1 heterozygotes, would have the lowest levels of reward related activity in both the ventral striatum during anticipation and in the orbitofrontal cortex during reward outcome. The gene discussed is SLC6A3; the disease is Parkinson disease.